戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 isations for HFpEF, double that of any other coexisting condition.
2 e or higher) and at least one weight-related coexisting condition.
3 nary disease (16,15.8%) were the most common coexisting conditions.
4 years or older or younger than 65 years with coexisting conditions.
5 hocytic leukemia (CLL) but not in those with coexisting conditions.
6 y improved outcomes in patients with CLL and coexisting conditions.
7 n patients with previously untreated CLL and coexisting conditions.
8 eristics, severity of illness, and burden of coexisting conditions.
9 e patients, indications for colonoscopy, and coexisting conditions.
10 rate the impact of multimorbidity related to coexisting conditions.
11 imited to patients who do not have extensive coexisting conditions.
12  minority groups, and has a higher burden of coexisting conditions.
13 tic evaluation for more than 100 potentially coexisting conditions.
14  idiopathic, whereas others are secondary to coexisting conditions.
15  providers of patients with multiple chronic coexisting conditions.
16 aseline body-mass index, and the presence of coexisting conditions.
17 ntrolled for demographic characteristics and coexisting conditions.
18 e heart failure, and diabetes were prominent coexisting conditions.
19  adjustment for sociodemographic factors and coexisting conditions.
20 lower effectiveness in persons with multiple coexisting conditions.
21 tribution of cardiovascular risk factors and coexisting conditions.
22 cross subgroups defined according to age and coexisting conditions.
23 n patients with previously untreated CLL and coexisting conditions.
24 ation status, previous infection status, and coexisting conditions.
25 nation status, previous infection status, or coexisting conditions.
26 al groups, age groups, and participants with coexisting conditions.
27 ents, VT was of nonendocardial origin with a coexisting condition also requiring cardiac surgery.
28 to participant age and status with regard to coexisting conditions and over time since receipt of the
29 rolling for potential confounders, including coexisting conditions and severity of illness.
30 t of quality did not vary by the presence of coexisting conditions and was not related to objective r
31 , timed 6-meter walk, presence of at least 1 coexisting condition, and self-rated health status.
32  overweight plus at least one weight-related coexisting condition, and without diabetes.
33  (70%) were male, 9 of 26 patients (35%) had coexisting conditions, and 22 (81%) were health care per
34 HF, LVEF is a dynamic factor related to sex, coexisting conditions, and drug therapy.
35 >75 years), the presence or absence of major coexisting conditions, and immunocompetence status.
36 ith adjustment for sociodemographic factors, coexisting conditions, and previous SARS-CoV-2 immunity
37  adjustment for demographic characteristics, coexisting conditions, and site of infarction (hazard ra
38 nagement of heart failure, the prevalence of coexisting conditions, and socioeconomic factors.
39 iary age, sex, index event, count of chronic coexisting conditions, and state of residence.
40 spitals after adjustment for age, sex, race, coexisting conditions, and the location of the infarctio
41 , and tobacco use were among the most common coexisting conditions, and their prevalence increased fr
42 hite, were more likely to be male, had fewer coexisting conditions, and were more likely to have unde
43 esources to support HF patients with complex coexisting conditions are needed to decrease hospitaliza
44 any patients with severe aortic stenosis and coexisting conditions are not candidates for surgical re
45                  Large-scale studies mapping coexisting conditions are, however, lacking.
46 o compare outcomes with regard to weight and coexisting conditions between the cohorts 5 years after
47                      Changes in body weight, coexisting conditions, cardiometabolic risk factors, and
48 ents with severe carotid-artery stenosis and coexisting conditions, carotid stenting with the use of
49                              The presence of coexisting conditions has a substantial effect on the ou
50 controlling for demographic characteristics, coexisting conditions, hospital, and surgery type.
51                  Endocarditis is an uncommon coexisting condition in bacterial meningitis but is asso
52                  Multimorbidity (two or more coexisting conditions in an individual) is a growing glo
53 the impact of chronic corticosteroid use for coexisting conditions in patients with Coronavirus Disea
54 ients are critically ill and frequently have coexisting conditions including sepsis and multiple orga
55            They are also more likely to have coexisting conditions, including autism and intellectual
56 n with other agents in patients with CLL and coexisting conditions is not known.
57                    The presence of extensive coexisting conditions may attenuate the survival benefit
58 6% (RSVPreF3 OA) and 38.9% (placebo) had >=1 coexisting condition of interest.
59 iations between condition type and number of coexisting conditions on receipt of overall good quality
60                    We examined the impact of coexisting conditions on the quality of care for hyperte
61 t loss in persons with either overweight and coexisting conditions or obesity is unknown.
62                                              Coexisting conditions or risk factors included current o
63    Four patients (29 percent) had no serious coexisting conditions or risk factors.
64  differences in demographic characteristics, coexisting conditions, or infarction site between patien
65  average sicker, having higher rates of most coexisting conditions, outpatient care, and prior hospit
66 zation rates versus differences in patients' coexisting conditions, quality of discharge planning, ph
67 ality did not differ according to age, race, coexisting conditions, self-reported performance status,
68                    After adjustment for age, coexisting conditions, severity and causes of heart fail
69                                  We compared coexisting conditions, severity of illness, and 30-day a
70                                              Coexisting conditions such as malnutrition and malaria m
71                        VHA patients had more coexisting conditions than Medicare patients.
72 specialty hospitals were less likely to have coexisting conditions than those being treated at genera
73 les were queried to identify the presence of coexisting conditions that confer a high risk of pneumoc
74  versus 29%, P=.02), and less likely to have coexisting conditions that might have predisposed to sud
75 evice to endarterectomy in 334 patients with coexisting conditions that potentially increased the ris
76                          Among those without coexisting conditions, the annual incidence of invasive
77 ss the severity of infarction, the number of coexisting conditions, treatments received, and the appr
78        Among patients with untreated CLL and coexisting conditions, venetoclax-obinutuzumab was assoc
79 % were frail or prefrail; the mean number of coexisting conditions was five in each group.
80  disease without dialysis, the prevalence of coexisting conditions was higher in the PAMV group.
81 than population norms, and the prevalence of coexisting conditions was similar to that among controls
82                              The most common coexisting conditions were diabetes mellitus (61.6%), ob
83 ients who were frail or had a high burden of coexisting conditions were eligible.
84                            The most frequent coexisting conditions were hypertension (60.0%), diabete
85 eated chronic lymphocytic leukemia (CLL) and coexisting conditions were randomized to 12 cycles of ve
86 th COVID-19 on long term corticosteroids for coexisting conditions while also seeking to compare outc
87 llitus (DM), a risk factor for, and frequent coexisting condition with, HF continues to increase in t
88 untreated chronic lymphocytic leukaemia, and coexisting conditions with a cumulative illness rating s
89 t patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic